Adverse events following yellow fever immunization: Report and analysis of 67 neurological cases in Brazil

Vaccine

Volumn 32, Issue 49, 2014, Pages 6676-6682

  Martins, Reinaldo de Menezes ^a   Pavão, Ana Luiza Braz ^a   de Oliveira, Patrícia Mouta Nunes ^a   dos Santos, Paulo Roberto Gomes ^a   Carvalho, Sandra Maria D ^b   Mohrdieck, Renate ^b   Fernandes, Alexandre Ribeiro ^c   Sato, Helena Keico ^d   de Figueiredo, Patricia Mandali ^e   von Doellinger, Vanessa dos Reis ^a   Leal, Maria da Luz Fernandes ^f   Homma, Akira ^a   Maia, Maria de Lourdes S ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Consultant to CIFAVI   (Brazil)

^c FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^d Instituto de Matemática e Estatística   (Brazil)

^e Member of CIFAVI   (Brazil)

^f Instituto de Technologia em Imunobiologicos   (Brazil)

Author keywords

Adverse event; Neurological autoimmune disease; Neurological disease; Neurotropic disease; Yellow fever vaccine

Indexed keywords

YELLOW FEVER VACCINE;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ADULT; ARTICLE; AUTOIMMUNE DISEASE; BRAZILIAN; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CONFIDENCE INTERVAL; FACIAL NERVE PARALYSIS; FEMALE; GROUPS BY AGE; GUILLAIN BARRE SYNDROME; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; INFECTION RISK; KINSBOURNE SYNDROME; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MENINGOENCEPHALITIS; MYELITIS; NEURITIS; NEUROLOGIC DISEASE; OPSOCLONUS MYOCLONUS SYNDROME; OPTIC NEURITIS; PASSIVE IMMUNIZATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SAMPLE SIZE; SCHOOL CHILD; STRATIFICATION; TUBERCULOUS MENINGITIS; YELLOW FEVER; ADOLESCENT; AGE; AGED; BRAZIL; CHEMICALLY INDUCED; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; INFANT; MIDDLE AGED; NEWBORN; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BRAZIL; CENTRAL NERVOUS SYSTEM DISEASES; CHILD; CHILD, PRESCHOOL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; YELLOW FEVER; YELLOW FEVER VACCINE; YOUNG ADULT;

EID: 84922615588     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.05.003     Document Type: Article

References (31)

1. Monath T.P. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines 2012, 11:427-483.
2. WHO Vaccines and vaccination against yellow fever. Wkly Epidemiol Rec 2013, 88:269-284.
3. Monath T.P., Gershman M., Staples J.E., Barrett D.T. Yellow fever vaccine. Vaccines 2013, Saunders, Philadelphia, [electronic edition]. 6th ed. S. Plotkin, W. Orenstein, P.A. Offit (Eds.).
4. Centers for Disease Control and Prevention Yellow fever vaccine. MMWR 2010, 59:1-27.
5. Theiler M., Smith H.H. The effect of prolonged cultivation in vitro upon the pathogenicity of yellow fever virus. J Exp Med 1937, 65:767-786.
6. Post P.R., Carvalho R., Freire M.S., Galler R. The early use of yellow fever virus strain 17D for vaccine production in Brazil-a review. Mem Inst Oswaldo Cruz 2001, 96:849-857.
7. Camacho L.A.B., Aguiar S.G., Freire M.S., Leal M.L.F., Nascimento J.P., Iguchi T., et al. Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial. Rev Saude Publica 2005, 39(3):413-420.
8. Stock N.K., Boschetti N., Herzog C., Appelhans M.S., Niedrig M. The phylogeny of yellow fever virus 17D vaccines. Vaccine 2012, 30:989-994.
9. Santos C.N.D., Post P.R., Carvalho R., Ferreira I.I., Rice C.M., Galler R. Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. Virus Res 1995, 35:35-41.
10. Marchevsky R.S., Freire M.S., Coutinho E.S.F., Galler R. Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys. Virology 2003, 316:55-63.
11. Galler R., Post P.R., Santos C.N., Ferreira I.I. Genetic variability among yellow fever virus 17D substrains. Vaccine 1998, 16:1024-1028.
12. Camacho L.A., Freire M.S., Leal M.L., Aguiar S.G., Nascimento J.P., Iguchi T., et al. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vacines: a randomized trial. Rev Saude Publica 2004, 38:671-678.
13. Martins R.M., Maia M.L.S., Santos E.M., Cruz R.L.S., Santos P.R.G., Deotti S.M., et al. Yellow fever vaccine post-marketing surveillance in Brazil. Proc Vaccinol 2010, 2:178-183.
14. Galler R., Pugachev K.V., Santos C.L.S., Ocran S.W., Jabor A.V., Rodrigues S.G., et al. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology 2001, 290:309-319.
15. Whittembury A., Ramirez G., Hernández H., Ropero A.M., Waterman S., Ticona M., et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 2009, 27:5974-5981.
16. Tapiainen T., Prevots R., Izurieta H.S., Abramson J., Bilynsky R., Bonhoeffer J., et al. Aseptic meningitis: case definition and guidelines for collection, analysis and presentation of immunization safety data. Vaccine 2007, 25:5793-5802.
17. Sejvar J.J., Kohl K.S., Bilynsky R., Blumberg D., Cvetkovich T., Galama J., et al. Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007, 25:5771-5792.
18. Khromava A.Y., Eidex R.B., Weld R.B., Weld L.H., Kohl K.S., Bradshaw R.D., et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005, 23:3256-3263.
19. Ministério da Saúde Departamento de Informática do Sistema Único de Saúde (DATASUS). Available at: http://www2.datasus.gov.br/DATASUS/index.php%3Farea=01.
20. Singhi P., Sahu J.K., Sarkar J., Bansai D. Clinical profile and outcome of children with opsoclonus-myoclonus syndrome. J Child Neurol 2014, 29:58-61.
21. Couto A.M., Salomão M.R., Schermann M.T., Mohrdieck R., Suzuki A., Carvalho S.M.D., et al. Transmission of yellow fever vaccine virus through breast-feeding-Brazil, 2009. MMWR 2010, 59:130-132.
22. Traiber C., Coelho-Amaral P., Ritter V.R.F., Winge A. Infant meningoencephalitis caused by yellow fever vaccine virus transmitted via breastmilk. J Pediatr (Rio J) 2011, 87:269-272.
23. McMahon A.W., Eidex R.B., Marfin A.A., Russell M., Sejvar J.J., Markoff L., et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine 2007, 25:1727-1734.
24. Breugelmans J.G., Lewis R.F., Agbenu E., Veit O., Jackson D., Domingo-Carrasco C., et al. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010. Vaccine 2013, 31:1819-1829.
25. Guimard T., Minjolle S., Polard E., Fily F., Zeller H., Michelet C., et al. Short report: incidence of yellow fever vaccine-associated neurotropic disease. Am J Trop Med Hyg 2009, 81:1141-1143.
26. Fernandes G.C., Camacho L.A.B., Carvalho M.S., Batista M., Almeida S.M.R. Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005. Vaccine 2007, 25:3124-3128.
27. Fox J.P., Lennette E.H., Manso C., Aguiar J.R.S. Encephalitis in man following vaccination with 17D yellow fever virus. Am J Hyg 1942, 36:117-142.
28. Rey M., Satge P., Collomb H., Guicheney A., Mar I.D., Niang I., et al. Aspects épidémiologiques et cliniques des encéphalites consécutives à la vaccination antiamarile. Bull Soc Méd Afr Noire Lgue fr 1966, 11:560-574.
29. Rosenthal S., Chen R. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health 1995, 85:1706-1709.
30. Chen R.T., Orenstein W.A. Epidemiologic methods in immunization programs. Epidemiol Rev 1996, 18:99-117.
31. Offit P.A., De Stefano F. Vaccine safety. Vaccines 2013, Saunders, Philadelphia, [electronic edition]. 6th ed. S. Plotkin, W. Orenstein, P.A. Offit (Eds.).